aortic stenosis

in review 3 min read Updated 2026-10-19
aortic stenosis

Severe = Vmax ≥4 m/s, mean gradient ≥40 mmHg, AVA ≤1.0 cm². Symptoms or LVEF <50% → valve replacement. Asymptomatic severe AS → exercise test to unmask symptoms; early intervention increasingly offered. TAVI for older patients, SAVR for younger low-risk patients, Heart Team in between. Symptomatic severe AS is preload- and rate-dependent → avoid vasodilators, hypovolaemia and tachycardia.


severity

MildModerateSevere
peak velocity (m/s)2.0–2.93.0–3.9≥4.0
mean gradient (mmHg)<2020–39≥40
AVA (cm²)>1.51.0–1.5≤1.0

Small AVA but low gradient — flow is too low to generate a gradient, or the AS is really moderate:

  • LVEF <50% → dobutamine stress echo: gradient rises and AVA stays ≤1.0 = true severe; AVA opens up = pseudo-severe (cardiomyopathy)
  • LVEF preserved (small hypertrophied LV) → CT aortic valve calcium score (>2000 AU men, >1200 AU women = severe likely)
  • confirmed severe low-gradient AS → treat as severe

when to intervene

  • symptomatic severe AS — exertional dyspnoea, angina, syncope; untreated survival is poor
  • asymptomatic severe AS + LVEF <50%
  • severe AS at the time of other cardiac surgery (CABG, aorta) — moderate AS reasonable too (ESC IIa)
  • asymptomatic → exercise test where safe; symptoms or BP fall on exercise = symptomatic
  • asymptomatic high-risk features → intervention reasonable: very severe AS (Vmax >5 m/s), rapid progression, markedly raised BNP
  • asymptomatic severe AS at low procedural risk → early intervention is now an alternative to watchful waiting: EARLY TAVR (2024) cut the composite of death, stroke and CV hospitalisation, driven by a quarter of the surveillance arm needing TAVI within 6 months

TAVI vs SAVR

  • older patients → TAVI (transfemoral, suitable anatomy); younger, low surgical risk → SAVR; in between → Heart Team decision on life expectancy vs valve durability
  • favour SAVR: bicuspid valve, young age, needs other cardiac surgery (CABG for complex CAD, aortic root), unsuitable anatomy
  • favour TAVI: frailty, porcelain aorta, chest radiation or deformity, prior CABG with patent grafts
  • TAVI → more new pacemakers and paravalvular leak; SAVR → more bleeding, AKI and new AF
  • PARTNER 3 (2019): TAVI at least as good as SAVR in low-risk patients at 1 year
  • balloon valvotomy: bridge only (unstable patient, urgent non-cardiac surgery)

After replacement → antithrombotics and valve choice in prosthetic heart valves.


medical management

haemodynamics in severe AS

Fixed outflow obstruction → cardiac output depends on preload and diastolic filling time.

  • avoid vasodilators (nitrates, aggressive ACEi/ARB) and over-diuresis in symptomatic severe AS → collapse
  • avoid tachycardia — shortens diastole
  • hypotension → phenylephrine or norepinephrine; intubation → vasopressor running before induction
  • hypertension with asymptomatic AS → treat (adds afterload), titrate carefully
  • no drug slows progression (statins don’t)
  • HF from severe AS → medical therapy must not delay valve replacement
  • follow-up echo: severe asymptomatic at least every 6 months; moderate at least annually; mild (young, no significant calcification) every 2–3 years; sooner if symptoms

key trials

TrialYearNComparisonResult
PARTNER 3 (2019)20191000TAVI vs SAVR, low-risk severe ASTAVI lower death/stroke/rehospitalisation at 1 y
EARLY TAVR (2024)2024901early TAVI vs surveillance, asymptomatic severe AScomposite ↓ ~50%; no difference in death or stroke

Prepared 2026-10-19. Not yet verified — check every number against the sources.

Key references

Suggest a correction aortic stenosis